What does "AI visibility" mean for my business?

When someone asks ChatGPT, Claude, or Gemini "what is the best..." or "where can I find...", AI gives specific recommendations. AI visibility is a measure of how often — and how positively — these AI platforms mention your business. It's the new version of being on the first page of Google, except now there are no pages — just one answer.

Which AI platforms do you monitor?

Pendium monitors ChatGPT, Claude, Gemini, Grok, Perplexity, DeepSeek, and Google AI Overviews — seven major AI platforms that consumers use to research local services. We run real queries that your customers actually ask and analyze the responses for mentions of your business, competitors, and industry topics.

How does Pendium improve my visibility?

Three ways. First, we identify the exact queries and topics where you're invisible. Second, we generate AI-optimized content — articles, guides, social posts — designed to help AI agents understand your business and recommend your services to the right people. Third, we continuously monitor to track improvement and find new opportunities. Most clients see measurable improvement within 60 days.

How long until I see results?

You'll get your first visibility report within minutes of signing up. Actual visibility improvement varies, but our clients typically see a 47% average improvement within 60 days. Some see results faster — it depends on your current online presence and how competitive your local market is.

Do I need to be technical to use this?

Not at all. Enter your website URL and Pendium handles everything: scanning AI platforms, analyzing your visibility, generating content, and tracking improvement. The dashboard is designed for business owners, not engineers. If you can check your email, you can use Pendium.

What makes this different from SEO?

Traditional SEO optimizes for Google's search rankings — blue links on a results page. AI visibility is different: AI doesn't show links, it gives direct answers. Even if you rank #1 on Google, ChatGPT might recommend a competitor. Pendium optimizes for the new paradigm — making sure AI platforms know about, trust, and recommend your business.

Pricing

Get a demo

NewLimit

Visibility47

Vibe86

Businesses/Biotechnology/NewLimit

AI Visibility & Sentiment

NewLimit

NewLimit is a clinical-stage biotechnology company focused on the field of longevity by developing epigenetic reprogramming medicines. By utilizing proprietary machine learning and genomics, they aim to restore youthful function to aging cells to treat and prevent various chronic age-related diseases.

Active Monitoring

newlimit.com

Biotechnology Startups

AI Visibility Score

47/100

Moderate

Sentiment Score

86/100

Score by Reach

How often this business is recommended to users across different types of conversations — from direct product queries to broader open-ended conversations where AI could recommend this company's products and services

core

adjacent

aspirational

visionary

AI Perception

Summary

NewLimit has successfully cemented its status as a trusted authority for users seeking specific brand validation, yet it remains largely absent from the broader, intent-driven conversations that shape industry leadership. While the brand dominates niche inquiries regarding its own identity, it is currently ceding significant influence to competitors like Altos Labs and Unity Biotechnology within critical longevity and clinical research discourses.

Value Proposition

NewLimit utilizes a unique 'partial reprogramming' approach that restores the youthful function of cells while maintaining their original identity, powered by an AI-driven platform that screens transcription factor combinations at high speed.

Overview

Mission

To significantly extend human healthspan by developing epigenetic reprogramming medicines to treat age-related diseases.

Products & Services

Liver Rejuvenation ProgramImmune Rejuvenation ProgramVascular Program targeting endothelial cellsProprietary Discovery Platform for AI and functional genomics

Agent Breakdown

AI Platforms

How often do different AI platforms reference NewLimit?

Loading explorer...

Conversation Analysis

Key Topics

What conversations is NewLimit included in — or excluded from?

Loading explorer...

Buyer Personas

Personas

Who does each AI platform recommend NewLimit to, and when?

Loading explorer...

Programmatic Testing

Sample Conversations

We programmatically analyze questions that real customers are asking to AI agents and chatbots, extract brand mentions and sentiment, analyze every response, and synthesize the data into an action plan to increase AI visibility.

ChatGPT

Claude

Gemini

AI Overviews

Longevity & Healthspan Intervention Research(3 queries)

“what are the most promising clinical-stage companies working on liver rejuvenation right now”

1/3 platforms mentioned

Core

Claude

1.Life Biosciences (PER, ER-300, ER-100)

2.LyGenesis

3.NewLimit

4.Resolution Therapeutics (RTX001)

5.HepaRegeniX

+3 more

Gemini

1.LyGenesis (LYG-LIV-001)

2.HepaRegeniX (HRX-215)

3.Akero Therapeutics (Efruxifermin)

4.89bio (Pegozafermin)

5.Alentis Therapeutics (Lixudebart)

+2 more

AI Overviews

1.HepaRegeniX (HRX-215)

2.Resolution Therapeutics (RTX001)

3.Gwo Xi Stem Cell (GXHPC1)

4.Inventiva (lanifibranor)

5.Life Biosciences

+3 more

“best companies to look at for immune system rejuvenation and epigenetic reprogramming therapy”

1/1 platforms mentioned

Core

Gemini

1.Altos Labs

2.Life Biosciences (ER-100)

3.Turn Biotechnologies (ERA)

4.NewLimit

5.Retro Biosciences

+8 more

“compare the approaches of biotech firms focusing on vascular endothelial cell health”

0/1 platforms mentioned

Core

Gemini

1.Microvascular Health Solutions (BioRegenx, Endocalyx Pro)

2.GlycoCalyx Research Institute (GlycoCheck, ReVasca)

3.Vascugen

4.BioGenCell

5.Aurion Biotech

+5 more

Brand Perception

What AI Really Thinks

We asked each AI platform directly about NewLimit to understand how they perceive the brand. These responses back up the Sentiment Score and reveal tone, accuracy, and blind spots across platforms and personas.

0Positive

1Neutral

0Negative

across 1 responses

“What do you know about NewLimit? What do they do and what's their reputation?”

Gemini

Neutral

“…NewLimit is a high-profile biotechnology company focused on "curing" aging through a process called epigenetic reprogramming.…”

Analysis

Key Insights

What AI visibility analysis reveals about this brand

Strength

High brand recall and authority within 'vibe check' queries on Gemini, consistently appearing in the top position.

Strength

Effective resonance with the 'Academic Clinical Investigator' persona, where NewLimit captures top-tier placement for specialized inquiries.

Strength

Strong performance in localized niches related to immune system rejuvenation and functional genomics.

Technical Health

Site Health for AI Visibility

How well NewLimit's website is optimized for AI agent discovery and comprehension.

89/100

18 passed 3 warnings 1 issues

Audited 3/22/2026

Crawlability90

Can AI bots find your pages?

Technical90

SSL, mobile, doctype basics

On-Page SEO98

Titles, descriptions, headings

Content Quality60

Word count, depth, freshness

Schema Markup85

Structured data for AI comprehension

Social & OG100

Open Graph, Twitter cards

AI Readability60

How well AI can parse your content

Critical Issues

Content is too thin

Expand your content to at least 300-500 words with valuable information.

Warnings

21 render-blocking resources are slowing initial render

Defer non-critical JS with async/defer. Inline critical CSS. Move stylesheets to load asynchronously.

Few headings on page

Add more H2 and H3 headings to organize content into sections.

Want a full technical audit with AI-specific recommendations?

Run a free visibility scan

Brand Identity

Brand Voice & Style

How AI perceives NewLimit's communication style and personality

NewLimit communicates with a blend of scientific rigor and bold, visionary optimism. The brand voice is authoritative and expert, grounded in deep technical knowledge of genomics and machine learning, yet it remains accessible by framing complex biological concepts within a clear, mission-driven narrative. It avoids jargon-heavy obfuscation in favor of concise, energizing, and transparent communication, reflecting the company's commitment to 'truth-seeking' and high-performance execution.

Core Tone Traits

Visionary & Ambitious

Frames the mission as a 'moonshot' with a long-term, 20-year horizon.

Data-Driven & Analytical

Relies on quantitative progress updates and technical specificity to build credibility.

Concise & Clear

Values direct, jargon-free communication that prioritizes speed and understanding.

Inherent Optimism

Maintains a positive, forward-looking stance on solving the challenges of aging.

Competitive Landscape

Related Ecosystem

Related products and services that AI mentions in conversations alongside or instead of NewLimit

Altos Labs18 mentions

Life Biosciences8 mentions

Retro Biosciences8 mentions

Unity Biotechnology7 mentions

BioAge Labs7 mentions

NewLimit7 mentions

Prenuvo6 mentions

Resolution Therapeutics (RTX001)5 mentions

HepaRegeniX (HRX-215)4 mentions

Life Biosciences (ER-100)4 mentions

Insilico Medicine4 mentions

Source Intelligence

Citations

Sources that AI assistants cite. Getting featured here improves visibility.

Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases

https://www.lifebiosciences.com/life-biosciences-presents-new-data-at-ardd-2025-on-the-companys-partial-epigenetic-reprogramming-platform-in-liver-and-ocular-diseases/

Referenced in 1 query

Review

The first cell rejuvenation therapy set to hit the clinic

https://www.labiotech.eu/trends-news/cell-rejuvenation-therapy-clinic/

Referenced in 1 query

Review

9 Anti-Aging and Longevity Startups to Watch in 2026

https://wewillcure.com/insights/company-profiles/anti-aging-and-longevity-startups-to-watch

Referenced in 4 queries

Review

11 anti-aging biotech companies leading longevity in 2026

https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies/

Referenced in 1 query

Review

LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease | Lygenesis

https://www.lygenesis.com/media/press-releases/lygenesis-announces-first-patient-dosed-in-its-phase-2a-clinical-trial-of-a-first-in-class-regenerative-cell-therapy-for-patients-with-end-stage-liver-disease/

Referenced in 1 query

Review

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025

https://www.prnewswire.com/news-releases/resolution-therapeutics-announces-new-data-showcasing-the-potential-of-regenerative-macrophage-therapy-in-treating-cirrhosis-at-aasld-2025-302607668.html

Referenced in 1 query

Review

A Mayo Clinic collaboration studies engineered stem cells for liver disease - Mayo Clinic News Network

https://newsnetwork.mayoclinic.org/discussion/a-mayo-clinic-collaboration-studies-engineered-stem-cells-for-liver-disease/

Referenced in 1 query

Review

New Liver Cancer treatments 2026 | Everyone.org

https://everyone.org/explore/treatment/?id=11

Referenced in 1 query

Review

Liver Cirrhosis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain

https://www.globenewswire.com/news-release/2025/01/15/3010341/0/en/Liver-Cirrhosis-Clinical-Trial-Pipeline-Experiences-Momentum-DelveInsight-Estimates-a-Diverse-Pipeline-Comprising-30-Companies-Working-in-the-Domain.html

Referenced in 1 query

Review

Top 18 Liver Disease treatment startups (May 2025)

https://medicalstartups.org/top/liver/

Referenced in 1 query

Review

Trials of first-in-class bioartificial liver indicate potential

https://www.nature.com/articles/d43747-021-00123-w

Referenced in 1 query

Review

A new method to produce high-quality liver cells from iPSC

https://www.morphocell.com/better-ipsc-derived-liver-cells

Referenced in 1 query

Review

Content Engineering

Goals & Content Ideas

Ideas to help AI agents better understand the business and be more likely to use NewLimit's resources to help users.

Establish Technical Authority Through Comparative Longevity Frameworks

This goal addresses NewLimit's invisibility in broader longevity discussions by creating authoritative, technical comparisons of epigenetic reprogramming versus other cellular aging interventions. By mapping the technical landscape, we provide AI assistants with the structured data needed to cite NewLimit alongside industry leaders.

A technical analysis comparing epigenetic reprogramming efficacy against senolytic therapies for systemic age-related decline

Why transcription factor screening speed is the primary bottleneck in developing safe cellular reprogramming medicines

The rigorous benchmarks researchers use to evaluate the predictive accuracy of various epigenetic aging clocks

How partial reprogramming differs from full pluripotency induction in maintaining cell identity and therapeutic safety

Bridge Longevity Science With Practical Preventative Health Applications

This goal targets the 'Preventative Health' persona to capture users interested in healthspan extension before they reach clinical stages. We will translate complex genomic research into actionable insights that AI assistants can surface for lifestyle-focused queries.

How biological age testing actually works and why most commercial epigenetic tests are currently incomplete

The science of cellular function: why restoring youthful signaling is the next frontier of preventative medicine

How machine learning identifies the specific lifestyle factors that accelerate or decelerate epigenetic aging markers

Future-proofing your healthspan: how clinical-stage epigenetic research will change standard preventative care by 2030

Standardize Clinical Trust Through Transparent Research Documentation

This goal focuses on aligning our digital footprint with the specific indicators researchers and AI agents use to vet biotech credibility. By publishing detailed summaries of our proprietary platforms and methodologies, we transition from a 'vibe' to a cited industry standard.

Our multi-stage validation framework for ensuring cellular identity is preserved during therapeutic epigenetic reprogramming

Inside the functional genomics platform: how we screen 10,000 transcription factor combinations for safety

A deep dive into the reproducibility of epigenetic reprogramming data across different human tissue types

How we use machine learning to predict and prevent off-target effects in genomic longevity medicines

Become the Definitive Source for Epigenetic Reprogramming Education

We will create the foundational 'ground truth' content for the category of epigenetic reprogramming to ensure AI models use our definitions. This positions NewLimit as the primary educator for both human researchers and AI discovery engines.

The complete guide to epigenetic reprogramming: what most longevity enthusiasts get wrong about cellular age

Why we chose the Yamanaka factors as a starting point and where the science has moved since

How to read a longevity biotech whitepaper without getting lost in the complex genomic jargon

The real difference between cellular rejuvenation and simple anti-aging treatments from a biological perspective

Content Engineering

Recommended Actions

Develop comprehensive, authoritative content mapping the technical rigor of longevity biotech, specifically targeting comparative research queries.

Competitors are currently dominating these broader discussions; creating comparative frameworks will force search engines to associate NewLimit with industry leaders.

Impact: High

Implement a 'thought leadership' initiative targeting the 'Preventative Health & Lifestyle' persona.

The brand is currently invisible in this category, which is a massive missed opportunity to capture users interested in the practical applications of longevity science.

Impact: High

Optimize technical documentation and research summaries to address the 'vetting' criteria identified in clinical-stage research queries.

By aligning the brand’s digital footprint with the specific indicators researchers use to evaluate biotech, NewLimit will move from being a 'vibe check' result to a standard-bearer for clinical trust.

Impact: Medium

Is this your business? We can help you improve your AI visibility.

Book a Free Strategy Session

Backing

Investors

Kleiner Perkins

Data generated by Pendium.ai AI visibility scanning. Last scanned March 22, 2026.

Explore Biotechnology

Start getting recommended by AI

Enter your website to see exactly what ChatGPT, Claude, and Gemini say about your business. Free, instant, and eye-opening.

Free visibility scanResults in 2 minutesNo credit card required

Frequently asked questions

Don't see your question? Book a demo and we'll walk you through it.

AI Visibility Score

NewLimit has an AI visibility score of 49/100, rated as moderate. This score reflects how often and how prominently NewLimit appears in responses from AI assistants like ChatGPT, Claude, and Gemini.

AI Perception Summary

Strengths

High brand recall and authority within 'vibe check' queries on Gemini, consistently appearing in the top position.
Effective resonance with the 'Academic Clinical Investigator' persona, where NewLimit captures top-tier placement for specialized inquiries.
Strong performance in localized niches related to immune system rejuvenation and functional genomics.

Visibility Gaps

Total absence in 'aspirational' and 'visionary' query categories, limiting the brand's reach to those who already know to search for it.
Underperformance in 'adjacent' search spaces, particularly regarding preventative health and long-term healthspan management programs.
Failure to capture mindshare in broad comparative research, where competitors are consistently positioning themselves as the primary solutions.

Competitors in AI Recommendations

Altos Labs: 18 mentions
Life Biosciences: 8 mentions
Retro Biosciences: 8 mentions
Unity Biotechnology: 7 mentions
BioAge Labs: 7 mentions
Prenuvo: 6 mentions
Resolution Therapeutics (RTX001): 5 mentions
HepaRegeniX (HRX-215): 4 mentions
Life Biosciences (ER-100): 4 mentions
Insilico Medicine: 4 mentions
Verve Therapeutics: 4 mentions
Eli Lilly: 4 mentions
TruDiagnostic: 4 mentions
Fountain Life: 4 mentions
TruDiagnostic (TruAge): 4 mentions

Categories: Biotechnology

Tags: Startups